Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$52.57
2.986.01%
al cierre: -
$51.76
-0.81-1.54%
After hour: 5:21 PM EDT
Comments
Loading...
Calificaciones de analistas, precios objetivo, pronóstico
BridgeBio Pharma Inc ha un obiettivo di prezzo di consenso pari a $53.83, stabilito in base alle ultime valutazioni degli analisti di 25. Le ultime 3 valutazioni degli analisti sono state rilasciate da Scotiabank, Oppenheimer y Cantor Fitzgerald il agosto 6, 2025, agosto 6, 2025 y julio 29, 2025. Con un obiettivo di prezzo medio di $71 tra le Scotiabank, Oppenheimer y Cantor Fitzgerald, c'è un implicito 37.17% upside per BridgeBio Pharma Inc da queste valutazioni degli analisti.
Firmas de analistas que realizan recomendaciones1
Scotiabank
Oppenheimer
Cantor Fitzgerald
Truist Securities
Piper Sandler
1calculado a partir de las calificaciones de los analistas
Calificaciones de analistas para BridgeBio Pharma
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
08/06/2025 | 10.12% | Scotiabank | $55 → $57 | Maintains | Sector Outperform | |||
08/06/2025 | 17.85% | Oppenheimer | $60 → $61 | Maintains | Outperform | |||
07/29/2025 | 83.54% | Cantor Fitzgerald | $95 → $95 | Reiterates | Overweight → Overweight | |||
07/21/2025 | 27.51% | Truist Securities | → $66 | Initiates | → Buy | |||
07/14/2025 | 31.38% | Piper Sandler | $63 → $68 | Maintains | Overweight | |||
07/14/2025 | 35.24% | Jefferies | → $70 | Initiates | → Buy | |||
07/11/2025 | 29.44% | Citigroup | $58 → $67 | Maintains | Buy | |||
07/09/2025 | 15.92% | Oppenheimer | $60 → $60 | Upgrade | Perform → Outperform | |||
06/30/2025 | 46.83% | Wells Fargo | $67 → $76 | Maintains | Overweight | |||
06/25/2025 | 4.33% | B of A Securities | $50 → $54 | Maintains | Buy | |||
06/17/2025 | -5.33% | Wolfe Research | → $49 | Initiates | → Outperform | |||
06/09/2025 | 8.19% | HC Wainwright & Co. | $53 → $56 | Maintains | Buy | |||
04/30/2025 | 6.26% | Scotiabank | $52 → $55 | Maintains | Sector Outperform | |||
04/30/2025 | 21.72% | Piper Sandler | $46 → $63 | Maintains | Overweight | |||
04/30/2025 | 39.1% | UBS | $65 → $72 | Maintains | Buy | |||
04/15/2025 | 2.4% | HC Wainwright & Co. | $49 → $53 | Maintains | Buy | |||
03/31/2025 | -3.4% | Redburn Atlantic | → $50 | Initiates | → Buy | |||
03/24/2025 | -3.4% | JP Morgan | $44 → $50 | Maintains | Overweight | |||
02/21/2025 | -5.33% | Citigroup | $45 → $49 | Maintains | Buy | |||
02/21/2025 | 83.54% | Cantor Fitzgerald | $95 → $95 | Reiterates | Overweight → Overweight | |||
02/21/2025 | 0.46% | Scotiabank | $49 → $52 | Maintains | Sector Outperform | |||
02/20/2025 | 83.54% | Cantor Fitzgerald | $70 → $95 | Maintains | Overweight | |||
02/13/2025 | -5.33% | HC Wainwright & Co. | $49 → $49 | Reiterates | Buy → Buy | |||
02/12/2025 | -5.33% | Scotiabank | $48 → $49 | Maintains | Sector Outperform | |||
12/23/2024 | -3.4% | Evercore ISI Group | $45 → $50 | Maintains | Outperform | |||
12/16/2024 | -5.33% | HC Wainwright & Co. | $49 → $49 | Reiterates | Buy → Buy | |||
11/25/2024 | -7.26% | Scotiabank | $45 → $48 | Maintains | Sector Outperform | |||
11/25/2024 | -13.06% | B of A Securities | $42 → $45 | Maintains | Buy | |||
11/25/2024 | -5.33% | HC Wainwright & Co. | $43 → $49 | Maintains | Buy | |||
11/15/2024 | -13.06% | Scotiabank | $44 → $45 | Maintains | Sector Outperform | |||
10/25/2024 | -16.92% | HC Wainwright & Co. | $43 → $43 | Reiterates | Buy → Buy | |||
10/17/2024 | -11.13% | Leerink Partners | $47 → $46 | Maintains | Outperform | |||
10/16/2024 | -14.99% | Scotiabank | → $44 | Initiates | → Sector Outperform | |||
10/03/2024 | — | Oppenheimer | — | Initiates | → Perform | |||
10/02/2024 | -16.92% | HC Wainwright & Co. | $43 → $43 | Reiterates | Buy → Buy | |||
09/30/2024 | -16.92% | HC Wainwright & Co. | $43 → $43 | Reiterates | Buy → Buy | |||
09/17/2024 | -16.92% | HC Wainwright & Co. | $43 → $43 | Reiterates | Buy → Buy | |||
09/16/2024 | 35.24% | Cantor Fitzgerald | $70 → $70 | Reiterates | Overweight → Overweight | |||
09/16/2024 | -16.92% | HC Wainwright & Co. | $43 → $43 | Reiterates | Buy → Buy | |||
09/11/2024 | -18.86% | B of A Securities | $42 → $42 | Maintains | Buy | |||
09/09/2024 | 35.24% | Cantor Fitzgerald | $70 → $70 | Reiterates | Overweight → Overweight | |||
09/04/2024 | -11.13% | Piper Sandler | → $46 | Initiates | → Overweight | |||
09/03/2024 | -16.92% | HC Wainwright & Co. | $43 → $43 | Reiterates | Buy → Buy | |||
08/27/2024 | -16.92% | HC Wainwright & Co. | $43 → $43 | Reiterates | Buy → Buy | |||
08/22/2024 | -16.92% | HC Wainwright & Co. | $43 → $43 | Reiterates | Buy → Buy | |||
08/07/2024 | -16.92% | JP Morgan | $46 → $43 | Maintains | Overweight | |||
08/07/2024 | -13.06% | Evercore ISI Group | $50 → $45 | Maintains | Outperform | |||
08/05/2024 | -16.92% | HC Wainwright & Co. | $43 → $43 | Reiterates | Buy → Buy | |||
08/02/2024 | -13.06% | Citigroup | $46 → $45 | Maintains | Buy | |||
07/01/2024 | 35.24% | Cantor Fitzgerald | $70 → $70 | Reiterates | Overweight → Overweight | |||
06/25/2024 | -18.86% | B of A Securities | $50 → $42 | Maintains | Buy | |||
06/20/2024 | -16.92% | HC Wainwright & Co. | $43 → $43 | Reiterates | Buy → Buy | |||
06/05/2024 | -16.92% | HC Wainwright & Co. | $43 → $43 | Reiterates | Buy → Buy | |||
05/30/2024 | -16.92% | HC Wainwright & Co. | $43 → $43 | Reiterates | Buy → Buy | |||
05/28/2024 | 35.24% | Cantor Fitzgerald | $70 → $70 | Reiterates | Overweight → Overweight | |||
05/28/2024 | -9.2% | UBS | $51 → $47 | Maintains | Buy | |||
05/20/2024 | -16.92% | HC Wainwright & Co. | $47 → $43 | Maintains | Buy | |||
05/14/2024 | -3.4% | Evercore ISI Group | → $50 | Initiates | → Outperform | |||
03/20/2024 | -13.06% | JP Morgan | $35 → $45 | Maintains | Overweight | |||
03/19/2024 | 35.24% | Cantor Fitzgerald | $60 → $70 | Maintains | Overweight | |||
03/11/2024 | 15.92% | Cantor Fitzgerald | $50 → $60 | Maintains | Overweight | |||
03/05/2024 | 2.4% | Mizuho | $60 → $53 | Maintains | Buy | |||
03/04/2024 | -9.2% | HC Wainwright & Co. | $47 → $47 | Reiterates | Buy → Buy | |||
02/23/2024 | -11.13% | Citigroup | $42 → $46 | Maintains | Buy | |||
01/31/2024 | -28.52% | BMO Capital | → $37 | Initiates | → Market Perform | |||
01/29/2024 | -9.2% | HC Wainwright & Co. | $22 → $47 | Maintains | Buy | |||
01/22/2024 | -3.4% | Cantor Fitzgerald | $50 → $50 | Reiterates | Overweight → Overweight | |||
11/07/2023 | -18.86% | Citigroup | → $42 | Initiates | → Buy | |||
10/24/2023 | -3.4% | Cantor Fitzgerald | → $50 | Initiates | → Overweight | |||
08/28/2023 | 15.92% | Mizuho | → $60 | Reiterates | Buy → Buy | |||
08/17/2023 | -26.58% | JP Morgan | $42 → $38 | Maintains | Overweight | |||
08/14/2023 | 15.92% | Mizuho | $50 → $60 | Maintains | Buy | |||
07/18/2023 | -3.4% | Goldman Sachs | $29 → $50 | Maintains | Buy | |||
07/18/2023 | -11.13% | Raymond James | $29 → $46 | Maintains | Outperform | |||
07/18/2023 | -36.24% | Jefferies | $24 → $33 | Downgrade | Buy → Hold | |||
05/08/2023 | -43.97% | Mizuho | $23 → $29 | Maintains | Buy | |||
04/19/2023 | -22.72% | Evercore ISI Group | → $40 | Initiates | → Outperform | |||
04/13/2023 | -47.84% | SVB Securities | $25 → $27 | Maintains | Outperform | |||
03/07/2023 | -55.56% | JP Morgan | $18 → $23 | Maintains | Overweight | |||
03/07/2023 | -45.9% | Goldman Sachs | $20 → $28 | Maintains | Buy | |||
03/07/2023 | -43.97% | Raymond James | $17 → $29 | Maintains | Outperform | |||
02/06/2023 | — | Cowen & Co. | — | Initiates | → Outperform | |||
01/23/2023 | -63.29% | SVB Leerink | $23 → $19 | Maintains | Outperform | |||
11/18/2022 | -63.29% | JP Morgan | $20 → $19 | Maintains | Overweight |
PREGUNTAS FRECUENTES
¿Cuál es el precio objetivo de las acciones de BridgeBio Pharma (BBIO)?
El último precio objetivo de BridgeBio Pharma (NASDAQ:BBIO) fue comunicado por Scotiabank el agosto 6, 2025. La firma de analistas fijó un precio objetivo para $57.00 que espera BBIO a rise dentro de 12 meses (un posible 10.12% upside). 43 firmas de analistas han reportado calificaciones en el último año.
¿Cuál es la calificación más reciente de los analistas sobre BridgeBio Pharma (BBIO)?
La última calificación de analistas para BridgeBio Pharma (NASDAQ:BBIO) fue proporcionada por Scotiabank, y BridgeBio Pharma mantuvo su sector outperform calificación.
¿Cuándo se produjo la última revisión al alza de BridgeBio Pharma (BBIO)?
La última revisión al alza de BridgeBio Pharma Inc se produjo en julio 9, 2025, cuando Oppenheimer elevó su precio objetivo a $60. Oppenheimer anteriormente tenía a perform para BridgeBio Pharma Inc.
¿Cuándo fue la última revisión a la baja de BridgeBio Pharma (BBIO)?
La última revisión a la baja de BridgeBio Pharma Inc se produjo en julio 18, 2023, cuando Jefferies cambió su precio objetivo de $24 a $33 para BridgeBio Pharma Inc.
¿Cuándo se publicará o actualizará la próxima calificación de los analistas para BridgeBio Pharma (BBIO)?
Los analistas llegan a las calificaciones de acciones después de hacer una investigación exhaustiva, que incluye revisar los estados financieros públicos, hablar con ejecutivos y clientes de BridgeBio Pharma, y escuchar las teleconferencias de ganancias. La mayoría de los analistas hacen esto cada tres meses, por lo que deberías recibir 4 calificaciones por empresa al año. La última calificación de BridgeBio Pharma se registró el agosto 6, 2025, por lo que la próxima calificación estará disponible en torno al agosto 6, 2026.
¿Es correcta la calificación de los analistas sobre BridgeBio Pharma (BBIO)?
Aunque las calificaciones son subjetivas y pueden cambiar, la última calificación de BridgeBio Pharma (BBIO) fue un mantuvo con un precio objetivo de $55.00 a $57.00. El precio actual al que cotiza BridgeBio Pharma (BBIO) es de $51.76, que es out of del rango previsto por el analista.
Explora calificaciones de analistas y precios objetivo sobre todos los valores.